Portfolio Update

3 January 2007 FINSBURY EMERGING BIOTECHNOLOGY TRUST PLC (the "Company") QUARTERLY STATEMENT OF INVESTMENTS In compliance with the Listing Rules - Chapter 21 Investment Entities (I)(ii), the Company discloses the following: * Investments valuing greater than 5% of the Company's gross assets comprise the following: Company Name Value of Investment % of Total at 31 December 2006 Portfolio Assets AMGEN COM USD0.0001 6,331,367 8.39 GENENTECH INC COM STK USD0.02 NPV 4,803,822 6.36 BIOGEN IDEC COM USD0.0005 4,743,469 6.28 GENZYME CORP GENERAL DIVISION COM USD0.01 4,275,646 5.66 INTERMUNE INC COM STK USD.001 4,192,274 5.55 * The ten largest investments held by the Company comprise the following: Company Name Value of Investment % of Total at 31 December 2006 Portfolio Assets AMGEN COM USD0.0001 6,331,367 8.39 GENENTECH INC COM STK USD0.02 NPV 4,803,822 6.36 BIOGEN IDEC COM USD0.0005 4,743,469 6.28 GENZYME CORP GENERAL DIVISION COM USD0.01 4,275,646 5.66 INTERMUNE INC COM STK USD.001 4,192,274 5.55 MEDIMMUNE INC COM USD0.01 3,173,594 4.20 GILEAD SCIENCES INC COM USD0.001 3,148,302 4.17 ACHILLION PHARMACEUTICALS USD0.001 2,823,355 3.74 GEN-PROBE INC USD0.0001 2,432,680 3.22 INDEVUS PHARMACEUTICALS INC USD0.001 2,414,685 3.20 For further information please contact: Mark Pope, Company Secretary Close Investments Limited Telephone: 020 7426 6219
UK 100

Latest directors dealings